175 related articles for article (PubMed ID: 25442763)
1. Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales.
Jain A; Linsell J; Briscoe K
Intern Med J; 2014 Dec; 44(12a):1258-9. PubMed ID: 25442763
[No Abstract] [Full Text] [Related]
2. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
[No Abstract] [Full Text] [Related]
3. Adjuvant docetaxel for node-positive breast cancer.
Ahluwalia MS; Daw HA
N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16135845
[No Abstract] [Full Text] [Related]
4. Docetaxel/Cyclophosphamide-induced ultraviolet recall dermatitis.
Basile FG; Creamer S
J Clin Oncol; 2011 Dec; 29(34):e840-1. PubMed ID: 22025156
[No Abstract] [Full Text] [Related]
5. Adjuvant docetaxel for node-positive breast cancer.
Noronha V
N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
[No Abstract] [Full Text] [Related]
6. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
7. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
Ishii N; Fujimori T; Kasagawa T; Udagawa I
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
[TBL] [Abstract][Full Text] [Related]
9. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.
Soong D; Haj R; Leung MG; Myers R; Higgins B; Myers J; Rajagopal S
J Clin Oncol; 2009 Sep; 27(26):e101-2. PubMed ID: 19652050
[No Abstract] [Full Text] [Related]
10. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
11. [Prevention of neutropenia during adjuvant taxotere therapy for breast cancer].
Mochalova AS; Koroleva IA
Vopr Onkol; 2012; 58(6):813-6. PubMed ID: 23600309
[No Abstract] [Full Text] [Related]
12. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Tervonen HE; Chen TYT; Lin E; Boyle FM; Moylan EJ; Della-Fiorentina SA; Beith J; Johnston A; Currow DC
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13125. PubMed ID: 31222826
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
14. Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
Ku M; Je NK
J Chemother; 2022 Dec; 34(8):534-542. PubMed ID: 34870568
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
17. [Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
Naito K; Oura S; Yoshimasu T; Nakamura R; Hirai Y; Kiyoi M; Miyasaka M; Okamura Y
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1913-6. PubMed ID: 20948255
[TBL] [Abstract][Full Text] [Related]
18. Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.
Tarcha FV; Baccarin ALC; Barros LADR; Alencar EBA; Del Giglio A; Cruz FJSM
Einstein (Sao Paulo); 2023; 21():eAO0486. PubMed ID: 38126660
[TBL] [Abstract][Full Text] [Related]
19. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
